Q BioMed (QBIO) 10-K 28 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Nov. 30, 2017	Feb. 27, 2018
Document and Entity Information
Entity Registrant Name	Q BIOMED INC.
Document Type	10-K
Document Period End Date	Nov. 30, 2017
Amendment Flag	false
Entity Central Index Key	1,596,062
Current Fiscal Year End Date	--11-30
Entity Common Stock, Shares Outstanding		13,918,284
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Public Float		$ 0
Trading Symbol	QBIO

Condensed Balance Sheets (unaud

Condensed Balance Sheets (unaudited) - USD ($)	Nov. 30, 2017	Nov. 30, 2016
Current assets:
Cash	$ 824,783	$ 1,468,724
Prepaid expenses	2,500
Total current assets	827,283	1,468,724
Total assets	827,283	1,468,724
Current liabilities:
Accounts payable and accrued expenses	463,539	497,936
Accounts payable - related party	7,500	70,502
Accrued interest payable		48,813
Convertible notes payable (See Note 5)		2,394,849
Note payable		100,152
Warrant liability		168,070
Total current liabilities	471,039	3,280,322
Long-term Liabilities:
Convertible notes payable (See Note 5)		231,517
Total long term liabilities		231,517
Total liabilities	471,039	3,511,839
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of November 30, 2017 and 2016
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,206,409 and 9,231,560 shares issued and outstanding as of November 30, 2017 and 2016, respectively	12,206	9,231
Additional paid-in capital	23,187,408	6,249,357
Accumulated deficit	(22,843,370)	(8,301,703)
Total Stockholders' Equity (Deficit)	356,244	(2,043,115)
Total Liabilities and Stockholders' Equity (Deficit)	$ 827,283	$ 1,468,724

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Nov. 30, 2017	Nov. 30, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, issued
Preferred stock, outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	12,206,409	9,231,560
Common stock, shares outstanding	12,206,409	9,231,560

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Operating expenses:
General and administrative expenses	$ 9,271,804	$ 5,032,257
Research and development expenses	3,099,971	1,314,250
Total operating expenses	12,371,775	6,346,507
Other (income) expense:
Interest expense	(760,314)	(480,285)
Interest income	138
Loss on conversion of debt	463,578	85,123
Loss on extinguishment of debt	76,251	(134,085)
Loss on issuance of convertible notes		(481,000)
Change in fair value of embedded conversion option	(810,017)	121,000
Change in fair value of warrant liability	$ (59,870)	$ 7,587
Loss on modification of Private Placement Units		(22,506)
Total other expenses	$ (2,169,892)	$ (825,004)
Net loss	$ (14,541,667)	$ (7,171,511)
Long-term Liabilities:
Net loss per share - basic and diluted	$ (1.39)	$ (0.81)
Weighted average shares outstanding, basic and diluted	10,466,648	8,861,212

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (unaudited) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Cash flows from operating activities:
Net loss	$ (14,541,667)	$ (7,171,511)
Adjustments to reconcile net loss to net cash used in operating activities
Issuance of common stock, warrants and options for services	6,399,585	4,131,114
Issuance of common stock for acquired in-process research and development	487,500	160,500
Change in fair value of embedded conversion option	810,017	(121,000)
Change in fair value of warrant liability	59,870	(7,587)
Loss on modification of Private Placement Units
Accretion of debt discount	628,026	413,894
Loss on conversion of debt	463,578	85,123
(Gain) loss on extinguishment of debt	76,251	(134,085)
Loss on issuance of convertible debt		481,000
Changes in operating assets and liabilities:
Prepaid expenses	(2,500)
Accounts payable and accrued expenses	(34,397)	439,134
Accrued expenses - related party	(63,002)	70,502
Accrued interest payable	132,288	66,389
Net cash used in operating activities	(5,584,451)	(1,545,259)
Cash flows from financing activities:
Proceeds received from issuance of convertible notes	2,500,000	2,495,000
Proceeds received from exercise of warrants	70,000
Proceeds received from issuance of note payable		150,000
Proceeds received for issuance of common stock and warrants , net of offering costs	2,370,510	237,575
Net cash provided by financing activities	4,940,510	2,882,575
Net increase (decrease) in cash	131,408	1,337,316
Cash at beginning of period	1,468,724	131,408
Cash at end of period	824,783	1,468,724
Non-cash financing activities:
Issuance of common stock upon conversion of convertible notes payable	5,608,514	295,764
Issuance of common stock and warrants in exchange for extinguishment of convertible notes payable	442,149
Issuance of common stock in exchange for extinguishment of OID Note	150,000
Issuance of warrants to settle accounts payable to related party		30,000
Modification of Series D convertible note recognized as extinguishment		294,085
Reclassification of warrant liability to equity	227,940
Cash paid for interest
Cash paid for income taxes

Shareholders Equity

Shareholders Equity - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, Amount at Nov. 30, 2015	$ 8,597
Beginning balance, Shares at Nov. 30, 2015	8,597,131	865,690	(1,130,192)	(255,905)
Issuance of common stocks and warrants for services, Amount	$ 342
Issuance of common stocks and warrants for services, Shares	341,543	3,300,772		3,301,114
Issuance of common stocks for acquire in-process research and development, Amount	$ 50
Issuance of common stocks for acquire in-process research and development, Shares	50,000	160,450		160,500
Issuance of common stocks for services to related parties, Amount	$ 3,375
Issuance of common stocks for services to related parties, Shares	3,375,000	25,650	(2,025)	27,000
Issuance of warrants to settle accounts payable to related party, Amount
Issuance of warrants to settle accounts payable to related party, Share		30,000		30,000
Acquisition and retirement of common stock, Amount	$ (3,750)
Acquisition and retirement of common stock, Shares	(3,750,000)	1,500	2,250
Issuance of common stocks upon conversion of convertible notes payable, Amount	$ 118
Issuance of common stocks upon conversion of convertible notes payable, Shares	118,128	380,768		380,886
Issuance of common stock and warrants in connection with Private Placement, net of warrant liabilities, Amount	$ 102
Issuance of common stock and warrants in connection with Private Placement, net of warrant liabilities, Shares	102,256	80,578		80,680
Modification of Private Placement Units, Amount	$ 7
Modification of Private Placement Units, Shares	7,502	22,499		22,506
Issuance of warrants for services to related party, Amount
Issuance of warrants for services to related party, Shares		830,000		830,000
Issuance of additional common stock to convertible notes holders, Amount	$ 26
Issuance of additional common stock to convertible notes holders, Share	25,641	98,179		98,205
Beneficial conversion feature in connection with issuance of convertible notes, Amont
Beneficial conversion feature in connection with issuance of convertible notes, Shares		526,400		526,400
Issuance of common stock in connection with OID Note, Amount	$ 15
Issuance of common stock in connection with OID Note, Shares	15,000	52,200		52,215
Net Loss			$ (7,171,511)	$ (7,171,511)
Ending balance, Amount at Nov. 30, 2016	$ 9,231			$ (2,043,115)
Ending balance, Shares at Nov. 30, 2016	9,231,560	6,249,357	(8,301,703)	(2,043,115)
Issuance of common stocks and warrants for services, Amount	$ 154
Issuance of common stocks and warrants for services, Shares	153,705	6,399,431		6,399,585
Issuance of common stocks for acquire in-process research and development, Amount	$ 500
Issuance of common stocks for acquire in-process research and development, Shares	125,000	547,800		548,000
Issuance of common stocks for services to related parties, Amount	$ 3,375
Issuance of common stocks for services to related parties, Shares	3,375,000	25,650	(2,025)	27,000
Acquisition and retirement of common stock, Amount	$ (3,750)
Acquisition and retirement of common stock, Shares	(3,750,000)	1,500	2,250
Issuance of common stocks upon conversion of convertible notes payable, Amount	$ 1,650
Issuance of common stocks upon conversion of convertible notes payable, Shares	1,650,379	5,972,236		5,973,886
Issuance of common stock and warrants in connection with Private Placement, net of warrant liabilities, Amount
Modification of Private Placement Units, Amount
Modification of Private Placement Units, Shares
Beneficial conversion feature in connection with issuance of convertible notes, Amont
Beneficial conversion feature in connection with issuance of convertible notes, Shares		645,000		645,000
Issuance of common stock in connection with OID Note, Amount	$ 47
Issuance of common stock in connection with OID Note, Shares	46,875	149,953		150,000
Issuance of common stock and warrants in exchange for extinguishment of convertible notes payable, Amount	$ 162
Issuance of common stock and warrants in exchange for extinguishment of convertible notes payable, Share	162,000	518,238		518,400
Issuance of common stock and warrants for cash, net of offering costs, Amount	$ 791
Issuance of common stock and warrants for cash, net of offering costs, Share	791,249	2,369,719		2,370,510
Reclassification of warrant liability to equity		227,940		227,940
Exercise of warrants, Amount	$ 20			$ 227,940
Exercise of warrants, Share	20,000	69,980		70,000
Net Loss			$ (14,541,667)	$ (14,541,667)
Ending balance, Amount at Nov. 30, 2017	$ 12,206			$ 356,244
Ending balance, Shares at Nov. 30, 2017	(12,206,409)	(23,187,408)	22,843,370	(356,244)

Organization of the Company and

Organization of the Company and Description of the Business	12 Months Ended
	Nov. 30, 2017
Accounting Policies [Abstract]
Organization of the Company and Description of the Business	Note 1 - Organization of the Company and Description of the Business Q BioMed Inc. (“Q BioMed” or “the Company”), incorporated in the State of Nevada on November 22, 2013, is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or spinoff new public companies. On December 7, 2016, the Company formed its wholly-owned subsidiary in Cayman Islands, “Q BioMed Cayman SEZC” (the “Subsidiary”).

Basis of Presentation

Basis of Presentation	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
Basis of Presentation	Note 2 - Basis of Presentation and Going Concern The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). The Company currently operates in one business segment focusing on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business. Going Concern The accompanying consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had a net loss of approximately $14.5 million and $7.2 million during the years ended November 30, 2017 and 2016, respectively, and had net cash used in operating activities of approximately $5.6 million and $1.5 million during years ended November 30, 2017 and 2016, respectively. These matter, amongst others, raise doubt about the Company’s ability to continue as a going concern. As of November 30, 2017, the Company has raised operating funds through contacts, high net-worth individuals and strategic investors. The Company has not generated any revenue from operations since inception and has limited assets upon which to commence its business operations. At November 30, 2017, the Company had cash and cash equivalents of approximately $825,000. On February 2, 2018, the Company netted approximately $4,915,000 from the registered sale of common stock and warrants to purchase common stock. The Company’s expected monthly burn rate is approximately $600,000. As such, management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management we will be forced to scale back the Company’s operations or cease our operations. Management has determined that there is substantial doubt about the Company's ability to continue as a going concern within one year after the consolidated financial statements are issued. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Nov. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include among others: the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of warrants on the Company’s stock and the valuation of embedded conversion options within the Company’s convertible notes payable. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal depository insurance coverage ("FDIC") of $250,000. At November 30, 2017, the Company had a cash balance on deposit that exceeded the balance insured by the FDIC limit by approximately $471,000 with one bank and was exposed to credit risk for amounts held in excess of the FDIC limit. The Company does not anticipate nonperformance by these institutions. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Fair value of financial instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended November 30, 2017 and 2016. The respective carrying value of cash and accounts payable approximated their fair values as they are short term in nature. Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company records a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the Statement of Operations. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a binomial model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Stock Based Compensation Issued to Nonemployees Common stock issued to non-employees for acquiring goods or providing services is recognized at fair value when the goods are obtained or over the service period. If the award contains performance conditions, the measurement date of the award is the earlier of the date at which a commitment for performance by the non-employee is reached or the date at which performance is reached. A performance commitment is reached when performance by the non-employee is probable because of sufficiently large disincentives for nonperformance. General and administrative expenses The significant components of general and administrative expenses consist of interest expense, bank fees, printing, filing fees, other office expenses, and business license and permit fees. Research and development The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made. Income Taxes Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company applies a more-likely-than-not recognition threshold for all tax uncertainties, which only allows the recognition of those tax benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities. As of November 30, 2017, the Company reviewed its tax positions and determined there were no outstanding, or retroactive tax positions with less than a 50% likelihood of being sustained upon examination by the taxing authorities, therefore this standard has not had a material effect on the Company. The Company’s policy for recording interest and penalties associated with audits is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest during the years ended November 30, 2017. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position. Recent accounting pronouncements In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business. The amendments in this Update is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Update may be adopted early. The Company adopted the provisions of ASC 2017-01 effective December 1, 2016. Adoption did not have a material impact on the Company's financial position, results of operations, or cash flows. In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting The ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

Loss per share

Loss per share	12 Months Ended
	Nov. 30, 2017
Earnings Per Share [Abstract]
Loss per share	Note 4 – Loss per share Basic net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive. Potentially dilutive securities November 30, 2017 November 30, 2016 Warrants (Note 10) 3,083,995 1,047,500 Convertible debt (Note 5) - 1,067,105 Options (Note 10) 450,000 # -

Convertible Notes

Convertible Notes	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
Convertible Notes	Note 5 – Convertible Notes November 30, 2017 November 30, 2016 Series A Notes: Principal value of 10%, convertible at $2.00 at November 30, 2016. $ — $ 12,500 Fair value of bifurcated embedded conversion option of Series A Notes — 12,000 Debt discount — (2,194 ) Carrying value of Series A Notes — 22,306 Series B Notes: Principal value of 10%, convertible at $2.00 at November 30, 2016. — 55,000 Fair value of bifurcated embedded conversion option of Series B Notes — 55,000 Debt discount — (19,229 ) Carrying value of Series B Notes — 90,771 Series C Notes: Principal value of 10%, convertible at $1.55 at November 30, 2016. — 576,383 Fair value of bifurcated embedded conversion option of Series C Notes — 838,000 Debt discount — (250,969 ) Carrying value of Series C Notes — 1,163,414 Series D Notes: Principal value of 10%, convertible at $1.85 at November 30, 2016. — 160,000 Debt discount — (140,961 ) Carrying value of Series D Notes — 19,039 Series E Notes: Principal value of 10%, convertible at $2.50 at November 30, 2016. — 180,000 Debt discount — (124,164 ) Carrying value of Series E Notes — 55,836 Secured Convertible Debenture: Principal value of 5%, convertible at $2.98 at November 30, 2016. — 1,500,000 Fair value of bifurcated contingent put option of Secured Convertible Debenture — 72,000 Debt discount — (297,000 ) Carrying value of Secured Convertible Debenture Note — 1,275,000 Total short-term carrying value of convertible notes $ — $ 2,394,849 Total long-term carrying value of convertible notes $ — $ 231,517 During the year ended November 30, 2017, all outstanding convertible notes and secured convertible debentures were converted by the holders or extinguished. See discussion below. During the year ended November 30, 2017 and 2016, the Company recognized interest expense of approximately $628,000 and $414,000, respectively, resulting from amortization of the debt discount for Series A, B, C, D and E Notes. Series A Notes The Series A convertible notes payable (the “Series A Notes”) are due and payable 18 months after issuance and bear interest at 10% per annum. At the election of the holder, outstanding principal and accrued but unpaid interest under the Series A Notes is convertible into shares of the Company’s common stock at any time prior to maturity at a conversion price per share equal to the higher of: (i) forty percent (40%) discount to the average closing price for the ten (10) consecutive trading days immediately preceding the notice of conversion or (ii) $1.25 per share. At maturity, any remaining outstanding principal and accrued but unpaid interest outstanding under the Series A Notes will automatically convert into shares of the Company’s common stock under the same terms. As of November 30, 2017, the Company has no Series A Notes outstanding. Series B Notes The Series B convertible notes payable (the “Series B Notes”) have the same terms as the Series A Notes. During the year ended November 30, 2016, the Company issued an additional of $105,000 in principal of Series B notes to third party investors. As of November 30, 2017, the Company has no Series B Notes outstanding. Series C Notes The Series C convertible notes payable (the “Series C Notes”) are due and payable 18 months after issuance and bear interest at 10% per annum. At the election of the holder, outstanding principal and accrued but unpaid interest under the Series C Notes is convertible into shares of the Company’s common stock at a conversion price per share equal to the lesser of a 40% discount to the average closing price for the 10 consecutive trading days immediately preceding the notice of conversion or $1.55, but in no event shall the conversion price be lower than $1.25 per share. If the average VWAP, as defined in the agreement, for the ten trading days immediately preceding the maturity date $5.00 or more, any remaining outstanding principal and accrued but unpaid interest outstanding under the Series C Notes will automatically convert into shares of the Company’s common stock under the same terms. The terms of the Series C Notes also provided that up until maturity date, the Company cannot enter into any additional, or modify any existing, agreements with any existing or future investors that are more favorable to such investor in relation to the Series D Note holders, unless, the Series C Note holders are provided with such rights and benefits (“Most Favored Nations Clause”). During the year ended November 30, 2016, the Company issued an additional of $550,000 in principal of Series C notes to third party investors.As of November 30, 2017, the Company has no Series C Notes outstanding. Series D Notes The Series D convertible notes payable (the “Series D Notes”) are due and payable 18 months after issuance and bear interest at 10% per annum. At the election of the holder, outstanding principal and accrued but unpaid interest under the Series D Notes is convertible into shares of the Company’s common stock at a fixed conversion price per share equal to $1.85. The Series D Notes automatically convert upon maturity at $1.85 per share if the ten trading days VWAP immediately preceding maturity is $5.00 or greater. Additionally, if the Company’s common shares are up-listed to a senior exchange such as the AMEX or NASDAQ, all monies due under the Series D Notes will automatically convert at $1.85 per share. During the year ended November 30, 2016, the Company issued $160,000 in principal of Series D notes to third party investors. The terms of the Series D Notes also included the Most Favored Nations Clause. The Most Favored Nations Clause was viewed as providing the Series D Note holder with down-round price protection. As such, the embedded conversion option in the Series D Note was separately measured at fair value upon issuance, with subsequent changes in fair value recognized in current earnings. On September 30, 2016, the Company amended the Most Favored Nations Clause of the Series D Notes to restrict the Company from taking dilutive action without the Series D note holders’ consent, effectively removing the down-round price protection. The amendment of the Series D Notes was recognized as an extinguishment of the originally issued Series D Notes, resulting in a gain on extinguishment of approximately $134,000. At the amendment date, the conversion price of the amended Series D Notes was below the quoted market price of the Company’s common stock. As such, the Company recognized a beneficial conversion feature equal to the intrinsic value of the conversion price on the amendment date, resulting in a discount to the amended Series D Notes of $160,000 with a corresponding credit to additional paid-in capital. The resulting debt discount is presented net of the related convertible note balance in the accompanying Consolidated Balance Sheets and is amortized to interest expense over the note’s term. As of November 30, 2017, the Company has no Series D Notes outstanding. Series E Notes The Series E convertible notes payable (the “Series E Notes”) are due and payable 18 months after issuance and bear interest at 10% per annum. At the election of the holder, outstanding principal and accrued but unpaid interest under the Series E Notes is convertible into shares of the Company’s common stock at a fixed conversion price per share equal to $2.50. The Series E Notes automatically convert upon maturity at $2.50 per share if the ten trading days VWAP immediately preceding maturity is $5.00 or greater. Additionally, if the Company’s common shares are up-listed to a senior exchange such as the AMEX or NASDAQ, all monies due under the Series E Notes will automatically convert at $2.50 per share. During the year ended November 30, 2016, the Company issued $180,000 in principal of Series E Notes to third party investors. At the issuance date, the conversion price of the Series E Notes was below the quoted market price of the Company’s common stock. As such, the Company recognized a beneficial conversion feature equal to the intrinsic value of the conversion price on the amendment date, resulting in a discount to the Series E Notes of approximately $141,000 with a corresponding credit to additional paid-in capital. The resulting debt discount is presented net of the related convertible note balance in the accompanying Consolidated Balance Sheets and is amortized to interest expense over the note’s term. As of November 30, 2017, the Company has no Series E Notes outstanding. Secured Convertible Debentures On November 29, 2016, the Company entered into a securities purchase agreement with an accredited investor to place Convertible Debentures (the “Debentures”) with a one-year term in the aggregate principal amount of up to $4,000,000. The initial closing occurred on November 30, 2016 when the Company issued a Debenture for $1,500,000. The second closing is scheduled for within three days of the date on which the Company registers for resale all of the shares of common stock into which the Debentures may be converted (the “Conversion Shares”). The Debentures bear interest at the rate of 5% per annum. In addition, the Company must pay to an affiliate of the holder a fee equal to 5% of the amount of the Debenture at each closing. The Debenture may be converted at any time on or prior to maturity at the lower of $4.00 or 93% of the average of the four lowest daily VWAP of the Company’s common stock during the ten consecutive trading days immediately preceding the conversion date, provided that as long as the Company is not in default under the Debenture, the conversion price may never be less than $2.00. The Company may not convert any portion of the Debenture if such conversion would result in the holder beneficially owning more than 4.99% of the Company’s then issued common stock, provided that such limitation may be waived by the holder. Any time after the six-month anniversary of the issuance of the Debenture, if the daily VWAP of the Company’s common stock is less than $2.00 for a period of twenty consecutive trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date, the Company shall make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall be in an amount equal to the sum of (i) the principal amount outstanding as of the Triggering Date divided by the number of such monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount being paid (up to a maximum of $300,000 in redemption premium) and (iii) accrued and unpaid interest as of each payment date. The Company may, no more than twice, obtain a thirty-day deferral of a monthly payment due as a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly payment. Each deferral payment may be paid by the issuance of such number of shares as is equal to the applicable deferral payment divided by a price per share equal to 93% of the average of the four lowest daily VWAP of the Company’s common stock during the ten consecutive Trading Days immediately preceding the due date in respect of such monthly payment begin deferred, provided that such shares issued will be immediately freely tradable shares in the hands of the holder. The Company also executed a Registration Rights Agreement pursuant to which it is required to file a registration statement for the resale of the shares of common stock into which the Debenture may be converted within 30 days of the initial closing. The Company is required to use its best efforts to cause such registration statement to be declared effective within 90 days of the initial closing. The Company also entered into a Security Agreement to secure payment and performance of its obligations under the Debenture and related agreements pursuant to which the Company granted the investor a security interest in all of its assets. The security interest granted pursuant to the Security Agreement terminates on (i) the effectiveness of the Registration Statement if the Company’s common stock closing price is greater than $2.00 for the twenty consecutive trading days prior to effectiveness or (ii) any time after the effectiveness of the registration statement that the Company’s common stock closing price is greater than $2.00 for the twenty consecutive trading days. Upon issuance of the Debentures, the Company recognized an aggregate debt discount of approximately $1.028 million, resulting from the recognition of beneficial conversion featuresaggregating $870,000 and bifurcated embedded derivatives aggregating $158,000. The beneficial conversion features were recognized as the intrinsic value of the conversion option on issuance of each Debentures. The monthly payment provision within the Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Statement of Operations. The Company estimated the fair value of the monthly payment provision, at issuance and at each reporting period, using probability analysis of the occurrence of a Triggering Date applied to the discounted maximum redemption premium for any given payment. The probability analysis utilized an expected volatility for the Company's common stock ranging from 101.58% to 146.26% and a risk free rates from 0.53% to 1.08%. The maximum redemption was discounted at 20%-22%, the calculated effective rate of the Debentures before measurement of the contingent put option. The fair value estimate is a Level 3 measurement. On October 3, 2017, the Company amended the Debentures to extend the maturity date from November 30, 2017 to November 30, 2018, and issued 25,641 restricted shares of its common stock to the holder of the Debentures as consideration for conversion. The fair value of the restricted shares was recognized as a loss on conversion. As of November 30, 2017, no Debentures were outstanding. Embedded Conversion Options In connection with the issuance of the Series A, B, C and the original issuance of the Series D Notes during the year ended November 30, 2016, the Company recognized a debt discount of approximately $750,000, and a loss on issuance of $481,000, which represents the excess of the fair value of the embedded conversion at initial issuance of $1.2 million over the principal amount of convertible debt issued. The embedded conversion feature is separately measured at fair value, with changes in fair value recognized in current operations. Management used a binomial valuation model, with fourteen steps of the binomial tree, to estimate the fair value of the embedded conversion option at issuance of the Series A, B, C and the original issuance of the Series D Notes issued during the year ended November 30, 2017 and 2016, with the following key inputs: Embedded derivatives in Convertible Notes at inception For the years ended November 30, 2017 2016 Stock price $ - $ 2.60 - $3.26 Terms (years) - 1.5 Volatility - 116.77% Risk-free rate - 0.51% - 0.76% Dividend yield - 0.00% Embedded derivatives in Convertible Notes at period end As of November 30, 2017 2016 Stock price $ - $ 3.43 Term (years) - 0.25 - 1.05 Volatility - 156.74% - 163.49% Risk-free rate - 0.48% - 0.80% Dividend yield - 0.00% As of November 30, 2017 and 2016, the embedded conversion options have an aggregate fair value of $0 and $977,000, respectively, and are presented on a combined basis with the related loan host in the Company’s Consolidated Balance Sheets. The tables below presents changes in fair value for the embedded conversion options, which is a Level 3 fair value measurement: Rollforward of Level 3 Fair Value Measurement for the Year Ended November 30, 2017 Balance at November 30, 2016 Issuance Net unrealized gain/(loss) Conversion Balance at November 30, 2017 $ 977,000 86,000 810,017 (1,873,017 ) $ - Rollforward of Level 3 Fair Value Measurement for the Year Ended November 30, 2016 Balance at November 30, 2015 Issuance Net unrealized gain/(loss) Settlements Balance at November 30, 2016 $ 229,000 1,303,000 (121,000 ) (434,000 ) $ 977,000 Conversions of debt The following conversions of occurred during the year ended November 30, 2017: Principal Shares Series A conversions $ 12,500 5,936 Series B conversions 55,000 27,995 Series C conversions 576,383 407,484 Series D conversions 160,000 91,782 Series E conversions 180,000 76,455 Secured Debenture conversions 4,000,000 1,040,727 Total $ 4,983,883 1,650,379 The following conversions debt occurred during the year ended November 30, 2016: Principal Shares Series A conversions $ 37,500 22,148 Series B conversions 100,000 51,111 Series C conversions 58,617 44,869 Total $ 196,117 118,128 As the embedded conversion option in each convertible note and in each Debenture had been separately measured at fair value or separately recognized as a beneficial conversion feature, the conversion of each instrument was recognized as an extinguishment of debt. The Company recognized an aggregate loss on conversion of debt of approximately $464,000 as the difference between the aggregate fair value of common stock issued to the holders of approximately $6.6 million and the aggregate net carrying value of the convertible notes and debentures, including the bifurcated conversion options.

Note Payable

Note Payable	12 Months Ended
	Nov. 30, 2017
Debt Disclosure [Abstract]
Note Payable	Note 6 – Note Payable As of November 30, 2017, and 2016, the Company had an outstanding promissory note of $0 and $150,000 (“OID Note”), respectively. The OID Note does not pay interest and matured on November 3, 2017. At the issuance date, the $150,000 OID Note was issued together with 15,000 restricted shares of the Company’s common stock for cash proceeds of $150,000. As such, the Company recognized a beneficial conversion feature, resulting in a discount to the OID Note of approximately $52,000 with a corresponding credit to additional paid-in capital. The resulting debt discount is presented net of the related convertible note balance in the accompanying consolidated balance sheet as of November 30, 2016 and was amortized to interest expense over the note’s term.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Nov. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Legal The Company is not currently involved in any legal matters arising in the normal course of business. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. Advisory Agreements The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received. The Company expects to issue an aggregate of approximately 27,000 shares of common stock subsequent to November 30, 2017 through the end term of arrangements, February 2018. Lease Agreement In December 2016, the Subsidiary entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ends in December 2019 and can be renewed for another three years. Rent expenses was classified within general and administrative expenses and was approximately $27,000 and $0 for the year ended November 30, 2017 and 2016. License Agreements Mannin On October 29, 2015, the Company entered into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby the Company was granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License. The technology platform may be expanded in scope beyond ophthalmological uses and may include cystic kidney disease and others. Pursuant to the Executive License, the Company has an option to purchase the Mannin IP within the next four years upon: (i) investing a minimum of $4,000,000 into the development of the intellectual property and (ii) possibly issuing additional shares of the Company’s common stock based on meeting pre-determined valuation and market conditions. The purchase price for the IP is $30,000,000 less the amount of cash paid by the Company for development and the value of the common stock issued to the vendor. During the years ended November 30, 2017 and 2016, the Company incurred approximately $1.9 million and $1.1 million, respectively, in research and development expenses to fund the costs of development of the eye drop treatment for glaucoma pursuant to the Exclusive License, of which an aggregate of $2.0 million and $0.7 million was already paid as of November 30, 2017 and 2016, respectively. Through November 30, 2017, the Company has funded an aggregate of $2.7 million to Mannin under the Exclusive License. In the event that: (i) the Company does not exercise the option to purchase the Mannin IP; (ii) the Company fails to invest the $4,000,000 within four years from the date of the Exclusive License; or (iii) the Company fails to make a diligent, good faith and commercially reasonable effort to progress the Mannin IP, all Mannin IP shall revert to the vendor and the Company will be granted the right to collect twice the monies invested through that date of reversion by way of a royalty along with other consideration which may be perpetual. Bio-Nucleonics On September 6, 2016, the Company entered into the Patent and Technology License and Purchase Option Agreement (the “BNI Exclusive License”). with Bio-Nucleonics Inc. (“BNI”) whereby the Company was granted a worldwide, exclusive, perpetual, license on, and option to, acquire certain BNI intellectual property (“BNI IP”) within the three-year term of the BNI Exclusive License. In exchange for the consideration, the Company agreed to, upon reaching various milestones, issue to BNI an aggregate of 110,000 shares of common stock that are subject to restriction from trading until commercialization of the product (approximately 12 months) and subsequent leak-out conditions, and provide funding to BNI for an aggregate of $850,000 in cash, of which the Company had paid $466,000 as of November 30, 2017. Once the Company has funded up to $850,000 in cash, the Company may exercise its option to acquire the BNI IP at no additional charge. In September 2016, the Company issued 50,000 shares of common stock, with a fair value of $160,500, to BNI pursuant to the BNI Exclusive License. During the years ended November 30, 2017 and 2016, the Company incurred approximately $467,000 and $219,000, respectively, in research and development expenses pursuant to the BNI Exclusive License. In the event that: (i) the Company does not exercise the option to purchase the BNI IP; (ii) the Company fails to make the aggregate cash payment within three years from the date of the Exclusive License; or (iii) the Company fails to make a diligent, good faith and commercially reasonable effort to progress the BNI IP, all BNI IP shall revert to BNI and the Company shall be granted the right to collect twice the monies invested through that date of reversion by way of a royalty along with other consideration which may be perpetual. Asdera On April 21, 2017, the Company entered into a License Agreement on Patent & Know-How Technology (“Asdera License”) with Asdera LLC (“Asdera”) whereby the Company was granted a worldwide, exclusive, license on certain Asdera intellectual property (“Asdera IP”). The initial cost to acquire the Asdera License is $50,000 and the issuance of 125,000 shares of the Company’s common stock, with a fair value of $487,500, of which the Company had fully paid and issued as of November 30, 2017, and recorded in research and development expenses in the accompanying Consolidated Statements of Operations. In addition to royalties based upon net sales of the product candidate, if any, the Company is required to make certain additional payments upon the following milestones: the filing of an investigational new drug application (the “IND”) with the US Food and Drug Administration (“FDA”); successful interim results of Phase II/III clinical trial of the product candidate; FDA acceptance of a new drug application; FDA approval of the product candidate; and achieving certain worldwide net sales. Subject to the terms of the Agreement, the Company will be in control of the development and commercialization of the product candidate and are responsible for the costs of such development and commercialization. The Company has undertaken a good-faith commitment to (i) initiate a Phase II/III clinical trial at the earlier of the two-year anniversary of the agreement or one year from the FDA’s approval of the IND and (ii) to make the first commercial sale by the fifth-anniversary of the agreement. Failure to show a good-faith effort to meet those goals would mean that the Asdera IP would revert to Asdera. Upon such reversion, Asdera would be obligated to pay the Company royalties on any sales of products derived from the Asdera IP until such time that Asdera has paid the Company twice the sum that the Company had provided Asdera prior to the reversion. OMRF OMRF License Agreement On June 15, 2017, the Company entered into a Technology License Agreement (“OMRF License Agreement”) with the Rajiv Gandhi Centre for Biotechnology, an autonomous research institute under the Government of India (“RGCB”), and the Oklahoma Medical Research Foundation (“OMRF” and together with RGCB, the “Licensors”), whereby the Licensors granted the Company a worldwide, exclusive, license on intellectual property related to Uttroside B (the “Uttroside B IP”). Uttroside B is a chemical compound derived from the plant Solanum nigrum Linn, also known as Black Nightshade or Makoi. The Company seeks to use the Uttroside B IP to create a chemotherapeutic agent against liver cancer. The initial cost to acquire the OMRF License Agreement is $10,000, which will be payable upon reaching certain agreed conditions. In addition to royalties based upon net sales of the product candidate, if any, the Company is required to make additional payments upon the following milestones: • the completion of certain preclinical studies (the “Pre-Clinical Trials”); • the filing of an investigational new drug application (the “IND”) with the US Food and Drug Administration (“FDA”) or the filing of the equivalent of an IND with the foreign equivalent of the FDA; • successful completion of each of Phase I, Phase II and Phase III clinical trials; • FDA approval of the product candidate; • approval by the foreign equivalent of the FDA of the product candidate; • achieving certain worldwide net sales; and • a change of control of QBIO. Subject to the terms of the Agreement, the Company will be in control of the development and commercialization of the product candidate and are responsible for the costs of such development and commercialization. The Company has undertaken a good-faith commitment to (i) fund the Pre-Clinical Trials and (ii) to initiate a Phase II clinical trial within six years of the date of the Agreement. Failure to show a good-faith effort to meet those goals would mean that the RGCB License Agreement would revert to the Licensors. No milestones have been reached to date on these license agreements.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Nov. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 - Related Party Transactions The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were approximately $420,000 and $300,000 for the year ended November 30, 2017 and 2016, respectively, and were included within general and administrative expenses in the accompanying Consolidated Statements of Operations.

Stockholders_ Equity Deficit

Stockholders’ Equity Deficit	12 Months Ended
	Nov. 30, 2017
Disclosure Text Block [Abstract]
Stockholders' Equity (Deficit)	Note 9 - Stockholders’ Equity (Deficit) As of November 30, 2017, and 2016, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock. Private Placement 2016 activity In May 2016, the Company entered into a subscription agreement with an investor in connection with the Company’s private placement (“May Private Placement”), generating gross proceeds of $50,000 by selling 20,000 units (each, Unit A”) at a price per Unit A of $2.50, with each Unit A consisting of one share of common stock and a two-year warrant to purchase one share of the Company’s common stock at an exercise price of $3.50 per share. The subscription agreement requires the Company to issue the May Private Placement investor additional common shares if the Company were to issue common stock or issue securities convertible or exercisable into shares of common stock at a price below $2.50 per share within 90 days from the closing of the May Private Placement. The additional shares are calculated as the difference between the common stock that would have been issued in the May Private Placement using the new price per unit less shares of common stock already issued pursuant to the May Private Placement. In August 2016, the Company consummated another private placement, for gross proceeds of approximately $10,000 by selling 6,500 units at a purchase price of $1.55 per unit. As a result, the Company issued the May Private Placement investor an additional 12,258 shares of common stock according to the agreement. In September 2016, the Company entered into a subscription agreement (the “Subscription Agreement”) with certain investors in connection with the Company’s private placement (“September Private Placement”), generating gross proceeds of $112,500 by selling 37,498 units (each, “Unit B”) at a price per Unit B of $3.00, with each Unit B consisting of one share of common stock and a two-year warrant to purchase one share of the Company’s common stock at an exercise price of $5.00 per share. In November 2016, the Company entered into additional Subscription Agreements with certain investors, generating gross proceeds of $65,000 by selling 26,000 units (each, “Unit C”) at a price per Unit C of $2.50, with each Unit C consisting of one share of common stock and a two-year warrant to purchase one share of the Company’s common stock at an exercise price of $4.00 per share. The Subscription Agreement requires the Company to issue the investor additional units if the Company were to issue common stock or issue securities convertible or exercisable into shares of common stock at a price below a specified price per share within 90 days from the closing of the private placement. The additional units are calculated as the difference between the common stock that would have been issued using the new price per unit less shares of common stock already issued pursuant to the private placement. Pursuant to the Subscription Agreement, the Company issued an additional of 7,502 units to the September Private Placement investors or no additional consideration. In addition, the Company also modified the exercise price of the warrants issued in the Unit B to $4.00 per share, which in effect, made the Unit B equivalent to Unit C (together as “Private Placement Unit”). The Company recorded approximately $41,000 as loss in connection with the issuance of additional units and modification of the warrants in the accompanying consolidated statements of operations, resulted from the value of the additional shares issued of approximately $23,000 and the change in warrant liability of approximately $19,000. 2017 activity On August 1, 2017, the Company closed its private placement (“August Private Placement”), selling an aggregate of 953,249 units (“Units”) at a price of $3.20 per Unit, for an aggregate cash proceeds of approximately $2.4 million, net of offering costs, and the retirement of $0.5 million in principal and accrued interest of the Debentures. A Unit consists of one common stock and one warrant exercisable for five years from the date of issuance into a share of the Company’s common stock at an exercise price of $4.50. In connection with the August Private Placement, the Company issued an aggregate of 39,246 warrants to the placement agent as consideration. These warrants have the same terms with the warrants issued in the August Private Placement. In January 2017, the Company issued 20,000 shares of the Company’s common stock upon receiving the notice to exercise the warrants at an exercise price of $3.50 included in Unit A sold in the private placement held in May 2017, for an aggregate purchase price of $70,000. Issued for services 2016 activity During the year ended November 30, 2016, the Company issued an aggregate of 341,543 shares of common stock, valued at approximately $1.6 million, and five-year warrants to purchase 175,000 shares of common stock at exercise prices ranging from of $1.45 to $3.00 per share for advisory services. The warrants vest 25% per quarter over the next year and were valued at $377,500 using inputs described in Note 9. The Company recognized the value of the warrants over the vesting period. In addition, the Company issued fully-vested five-year warrants to a stockholder, a director and general counsel of the Company to purchase an aggregate of 375,000 shares of common stock at strike prices ranging from $1.45 to $4.15 per share. The warrants were valued at $957,500 using inputs described in Note 9. The warrants were issued for services and settlement of a $30,000 in accounts payable. In July 2016, the Company issued five-year warrants to purchase an aggregate of 300,000 shares of the Company’s common stock at $1.45 to two members of the Company’s Board of Director for their compensation for their board services. The warrants vest 25% per quarter starting on grant date and were valued at $390,000 using inputs described in Note 9. The Company recognized the value of the warrants over the vesting period. The Company recognized general and administrative expenses of approximately $4.1 million, as a result of these transactions during the year ended November 30, 2016. The estimated unrecognized stock-based compensation associated with these agreements is approximately $399,000 and will be recognized over the next 0.2 year. 2017 activity The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services. During the year ended November 30, 2017, the Company issued an aggregate of 153,705 shares of the Company common stock to various vendors for investor relation and introductory services, valued at approximately $0.7 million based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying consolidated statements of operations for the year ended November 30, 2017. In September 2017, the Company issued warrants to purchase up to 50,000 shares of the Company’s common stock to two vendors for services. The warrants are exercisable for three years at a per share price of $4.00. On October 3, 2017, the Company amended the Debentures to extend the maturity date from November 30, 2017 to November 30, 2018, and issued 25,641 restricted shares of its common stock to the holder of the Debentures as consideration.

Warrants

Warrants	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
Warrants	Note 10 - Warrants and Options Warrant Liability As of November 30, 2016, the Company had outstanding warrants issued as part of the private placement units initially classified as liabilities because the exercise price may be adjusted downward, in certain circumstances, for a ninety-day period following their initial issuance. Warrant liabilities were measured at fair value, with changes in fair value recognized each reporting period in the Statement of Operations. The warrants ceased being liability classified at the conclusion of the ninetieth day from issuance. As a result, an aggregate of approximately $228,000 in warrant liability was reclassified to equity during the year ended November 30, 2017. All other warrants are equity classified. In September 2017, the Company issued equity-classified warrants to purchase up to 50,000 shares of the Company’s common stock to two vendors for services. The warrants are exercisable for three years at a per share price of $4.00. The warrant liability is a Level 3 fair value measurement, recognized on a recurring basis. Both observable and unobservable inputs may be used to determine the fair value of positions that the Company has classified within the Level 3 category. As a result, the unrealized gains and losses for liabilities within the Level 3 category may include changes in fair value that were attributable to both observable inputs (e.g., changes in market interest rates) and unobservable inputs (e.g., probabilities of the occurrence of an early termination event). Fair value of warrant liability at November 30, 2016 $ 168,070 Issuance of new warrant liability - Change in fair value of warrant liability 59,870 Reclassification of warrant liability to equity (227,940 ) Fair value of warrant liability at November 30, 2017 $ - Summary of warrants The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at November 30, 2017 and 2016 and the changes during the period then ended: Weighted Average Weighted Average Remaining Contractual Warrants Exercise Price Intrinsic Value Life (years) Outstanding at November 30, 2015 100,000 $ 2.18 $ 1,370,000 4.80 Issued 984,998 $ 2.67 $ 1,033,000 3.97 Expired (37,498 ) $ 5.00 $ - - Outstanding at November 30, 2016 1,047,500 $ 2.54 $ 1,158,000 4.10 Issued 2,056,495 $ 4.25 $ 512,960 4.46 Exercised (20,000 ) $ 3.50 $ 19,800 - Outstanding at November 30, 2017 3,083,995 $ 3.67 $ 2,539,185 4.02 Exercisable at November 30, 2017 2,323,245 $ 3.56 $ 2,170,618 3.90 Fair value of all outstanding warrants was calculated with the following key inputs: For the year ended November 30, 2017 For the year ended November 30, 2016 Stock price $3.40 - $5.60 $1.60 - $4.15 Term (years) 1.75 - 5.0 2.0 - 5.0 Volatility 129.64% - 143.47% 101.13% - 138.69% Risk-free rate 1.42% - 2.14% 0.76% - 1.83% Dividend yield 0.00% 0.00% Options issued for services The following represents a summary of all outstanding options to purchase the Company’s common stock at November 30, 2017 and changes during the period then ended: Weighted Average Weighted Average Remaining Contractual Options Exercise Price Intrinsic Value Life (years) Outstanding at November 30, 2016 - $ - $ - - Issued 450,000 $ 4.00 $ 220,500 4.51 Exercised - $ - $ - - Outstanding at November 30, 2017 450,000 $ 4.00 $ 220,500 4.51 Exercisable at November 30, 2017 112,500 $ 4.00 $ 55,125 4.51 Stock-based Compensation The Company recognized general and administrative expenses of approximately $6.4 million and $4.1 million, as a result of the shares, outstanding warrants and options issued to consultants and employees during the year ended November 30, 2017 and 2016, respectively. As of November 30, 2017, the estimated unrecognized stock-based compensation associated with these agreements is approximately $437,000 and will be recognized over the next 0.15 year.

Income Taxes

Income Taxes	12 Months Ended
	Nov. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 11 - Income Taxes On December 22, 2017, the United States enacted new tax legislation, the Tax Cuts and Jobs Act. The Company is currently in the process of evaluating the impact this law will have on the consolidated financial statements and calculating the related impact to the Company’s tax expense. The Company expects the largest impact to the company from this legislation to be from the provisions that lower the corporate tax rate to 21% beginning on January 1, 2018, and impose tax on earnings outside the United States that have previously not been subject to United States tax, which must be paid beginning in fiscal 2019 through fiscal 2026. The adjustments to the Company’s tax expense for this legislation will be recorded beginning in the period of enactment and are not expected to materially affect the consolidated financial statements, given the Company’s net deferred tax asset position has a full valuation allowance. At November 30, 2017, the Company has a net operating loss (“NOL”) carryforward for Federal and state income tax purposes totaling approximately $10.0 million available to reduce future taxable income which, if not utilized, will begin to expire in the year 2037. The NOL carry forward is subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Under the Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss carryforwards to offset taxable income may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of November 30, 2017. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company’s history of operating losses since inception, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of November 30, 2017 and 2016. The valuation allowance increased by approximately $5.9 million and $2.5 million for the fiscal years ended November 30, 2017 and 2016. The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following: As of November 30, 2017 2016 Deferred tax assets: Net-operating loss carryforward $ 3,810,498 $ 885,120 Stock-based compensation 4,466,254 1,685,262 License agreement 595,780 293,433 Tax amortization for license agreement (102,747) - Charitable contributions 387 - Total Deferred Tax Assets 8,770,172 2,863,815 Valuation allowance (8,770,172) (2,863,815) Deferred Tax Asset, Net of Allowance $ - $ - A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: For the year ended November 30, 2017 2016 Statutory Federal Income Tax Rate (34.0) % (34.0) % State and Local Taxes, Net of Federal Tax Benefit (10.3) % (4.7) % Loss on conversion of debt 1.4 % 0.5 % Gain/ loss on extinguishment of convertible note 0.2 % (0.7) % Change in fair value of embedded conversion option and related accretion of interest expense 4.4 % 1.6 % Change in fair value of warrant liability 0.2 % 0.0 % Loss on modification of Private Placement Units 0.0 % 0.2 % Loss on issuance of convertible debt 0.0 % 2.6 % Non-U.S. operations 0.3 % 0.0 % Change in Valuation Allowance 37.8 % 34.5 % Income Taxes Provision (Benefit) 0.0 % 0.0 % The Company's major tax jurisdictions are the United States and New York. All of the Company's tax years will remain open starting 2013 for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. The Company does not have any tax audits pending.

Subsequent Events

Subsequent Events	12 Months Ended
	Nov. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 12 - Subsequent Events On February 1, 2018, the Company sold an aggregate of 1,711,875 shares of common stock, and 1,711,875 warrants to purchase shares of common stock, in a registered public offering for gross proceeds of approximately $5,478,000. The warrants are exercisable for five years at $3.20 per share. The Company paid placement agent commissions of approximately $418,000 and issued the placement agent five-year warrants to purchase 81,688 shares of common stock at $3.84 per share. After the placement agents’ commissions and other offering expenses, the Company netted approximately $4,915,000 of proceeds. The Company intends to use the net proceeds from the offering to: i) launch our non-opioid FDA approved Strontium Chloride 89 USP Injection (SR89), a therapeutic drug for the treatment of skeletal pain associated with metastatic cancers; ii) focus on the clinical planning and IND filing for a Phase 4 post-marketing study to expand the indication of the approved SR89; iii) complete pre-IND studies and the filing of an IND for a phase II/III clinical program to test the efficacy of QBM-001, our product candidate for the treatment of young children with a rare autistic spectrum disorder that severely inhibits their ability to communicate; iv) continue development work on our novel chemotherapeutic drug for liver cancer; and v) further the optimization and pre-clinical testing of our glaucoma drug Man-01 for the treatment of open angle glaucoma.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Nov. 30, 2017
Disclosure Text Block [Abstract]
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include among others: the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of warrants on the Company’s stock and the valuation of embedded conversion options within the Company’s convertible notes payable.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal depository insurance coverage ("FDIC") of $250,000. At November 30, 2017, the Company had a cash balance on deposit that exceeded the balance insured by the FDIC limit by approximately $471,000 with one bank and was exposed to credit risk for amounts held in excess of the FDIC limit. The Company does not anticipate nonperformance by these institutions. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair value of financial instruments	Fair value of financial instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended November 30, 2017 and 2016. The respective carrying value of cash and accounts payable approximated their fair values as they are short term in nature.
Embedded Conversion Features	Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company records a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the Statement of Operations. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a binomial model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
Stock Based Compensation Issued to Nonemployees	Stock Based Compensation Issued to Nonemployees Common stock issued to non-employees for acquiring goods or providing services is recognized at fair value when the goods are obtained or over the service period. If the award contains performance conditions, the measurement date of the award is the earlier of the date at which a commitment for performance by the non-employee is reached or the date at which performance is reached. A performance commitment is reached when performance by the non-employee is probable because of sufficiently large disincentives for nonperformance.
General and administrative expenses	General and administrative expenses The significant components of general and administrative expenses consist of interest expense, bank fees, printing, filing fees, other office expenses, and business license and permit fees.
Research and development	Research and development The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made.
Income Taxes	Income Taxes Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company applies a more-likely-than-not recognition threshold for all tax uncertainties, which only allows the recognition of those tax benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities. As of November 30, 2017, the Company reviewed its tax positions and determined there were no outstanding, or retroactive tax positions with less than a 50% likelihood of being sustained upon examination by the taxing authorities, therefore this standard has not had a material effect on the Company. The Company’s policy for recording interest and penalties associated with audits is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest during the years ended November 30, 2017. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.
Recent accounting pronouncements	Recent accounting pronouncements In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business. The amendments in this Update is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Update may be adopted early. The Company adopted the provisions of ASC 2017-01 effective December 1, 2016. Adoption did not have a material impact on the Company's financial position, results of operations, or cash flows. In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting The ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

Loss per share (Table)

Loss per share (Table)	12 Months Ended
	Nov. 30, 2017
Earnings Per Share [Abstract]
Loss per share	Potentially dilutive securities November 30, 2017 November 30, 2016 Warrants (Note 10) 3,083,995 1,047,500 Convertible debt (Note 5) - 1,067,105 Options (Note 10) 450,000 # -

Convertible Notes (Tables)

Convertible Notes (Tables)	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
Convertible Notes	November 30, 2017 November 30, 2016 Series A Notes: Principal value of 10%, convertible at $2.00 at November 30, 2016. $ - $ 12,500 Fair value of bifurcated embedded conversion option of Series A Notes - 12,000 Debt discount - (2,194) Carrying value of Series A Notes - 22,306 Series B Notes: Principal value of 10%, convertible at $2.00 at November 30, 2016. - 55,000 Fair value of bifurcated embedded conversion option of Series B Notes - 55,000 Debt discount - (19,229) Carrying value of Series B Notes - 90,771 Series C Notes: Principal value of 10%, convertible at $1.55 at November 30, 2016. - 576,383 Fair value of bifurcated embedded conversion option of Series C Notes - 838,000 Debt discount - (250,969) Carrying value of Series C Notes - 1,163,414 Series D Notes: Principal value of 10%, convertible at $1.85 at November 30, 2016. - 160,000 Debt discount - (140,961) Carrying value of Series D Notes - 19,039 Series E Notes: Principal value of 10%, convertible at $2.50 at November 30, 2016. - 180,000 Debt discount - (124,164) Carrying value of Series E Notes - 55,836 Secured Convertible Debenture: Principal value of 5%, convertible at $2.98 at November 30, 2016. - 1,500,000 Fair value of bifurcated contingent put option of Secured Convertible Debenture - 72,000 Debt discount - (297,000) Carrying value of Secured Convertible Debenture Note - 1,275,000 Total short-term carrying value of convertible notes $ - $ 2,394,849 Total long-term carrying value of convertible notes $ - $ 231,517
Schedule of Share-based Compensation, Activity	Embedded derivatives in Convertible Notes at inception For the years ended November 30, 2017 2016 Stock price $ - $ 2.60 - $3.26 Terms (years) - 1.5 Volatility - 116.77% Risk-free rate - 0.51% - 0.76% Dividend yield - 0.00%
Fair value of the embedded conversion	Embedded derivatives in Convertible Notes at period end As of November 30, 2017 2016 Stock price $ - $ 3.43 Term (years) - 0.25 - 1.05 Volatility - 156.74% - 163.49% Risk-free rate - 0.48% - 0.80% Dividend yield - 0.00%
Schedule of Stock Options Roll Forward	Rollforward of Level 3 Fair Value Measurement for the Year Ended November 30, 2017 Balance at November 30, 2016 Issuance Net unrealized gain/(loss) Conversion Balance at November 30, 2017 $ 977,000 86,000 810,017 (1,873,017 ) $ - Rollforward of Level 3 Fair Value Measurement for the Year Ended November 30, 2016 Balance at November 30, 2015 Issuance Net unrealized gain/(loss) Settlements Balance at November 30, 2016 $ 229,000 1,303,000 (121,000 ) (434,000 ) $ 977,000
Conversions of convertible notes	The following conversions of occurred during the year ended November 30, 2017: Principal Shares Series A conversions $ 12,500 5,936 Series B conversions 55,000 27,995 Series C conversions 576,383 407,484 Series D conversions 160,000 91,782 Series E conversions 180,000 76,455 Secured Debenture conversions 4,000,000 1,040,727 Total $ 4,983,883 1,650,379 The following conversions debt occurred during the year ended November 30, 2016: Principal Shares Series A conversions $ 37,500 22,148 Series B conversions 100,000 51,111 Series C conversions 58,617 44,869 Total $ 196,117 118,128

Warrants and Options (Tables)

Warrants and Options (Tables)	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
Fair value of warrant liability	Fair value of warrant liability at November 30, 2016 $ 168,070 Issuance of new warrant liability - Change in fair value of warrant liability 59,870 Reclassification of warrant liability to equity (227,940 ) Fair value of warrant liability at November 30, 2017 $ -
Summary of outstanding warrants	Weighted Average Weighted Average Remaining Contractual Warrants Exercise Price Intrinsic Value Life (years) Outstanding at November 30, 2015 100,000 $ 2.18 $ 1,370,000 4.80 Issued 984,998 $ 2.67 $ 1,033,000 3.97 Expired (37,498 ) $ 5.00 $ - - Outstanding at November 30, 2016 1,047,500 $ 2.54 $ 1,158,000 4.10 Issued 2,056,495 $ 4.25 $ 512,960 4.46 Exercised (20,000 ) $ 3.50 $ 19,800 - Outstanding at November 30, 2017 3,083,995 $ 3.67 $ 2,539,185 4.02 Exercisable at November 30, 2017 2,323,245 $ 3.56 $ 2,170,618 3.90
Fair value of the warrant	For the year ended November 30, 2017 For the year ended November 30, 2016 Stock price $3.40 - $5.60 $1.60 - $4.15 Term (years) 1.75 - 5.0 2.0 - 5.0 Volatility 129.64% - 143.47% 101.13% - 138.69% Risk-free rate 1.42% - 2.14% 0.76% - 1.83% Dividend yield 0.00% 0.00%
Fair value of warrant liability	Weighted Average Weighted Average Remaining Contractual Options Exercise Price Intrinsic Value Life (years) Outstanding at November 30, 2016 - $ - $ - - Issued 450,000 $ 4.00 $ 220,500 4.51 Exercised - $ - $ - - Outstanding at November 30, 2017 450,000 $ 4.00 $ 220,500 4.51 Exercisable at November 30, 2017 112,500 $ 4.00 $ 55,125 4.51

Loss per share (Details)

Loss per share (Details) - USD ($)	Nov. 30, 2017	Nov. 30, 2016
Earnings Per Share [Abstract]
Warrants	3,083,995	1,047,500
Convertible Debt		$ 1,067,105
Conversion option	450,000

Basis of Presentation (Detail N

Basis of Presentation (Detail Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016	Aug. 31, 2017
Notes to Financial Statements
Accumulated deficit			$ 1,400,000
Working capital deficit			$ 1,900,000
Net loss	$ 14,500,000	$ 7,200,000
Net cash used in operating activities	$ 5,600,000	$ 1,500,000

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Accounting Policies [Abstract]
Federal depository insurance coverage		$ 250,000
Outstanding convertible notes payable	$ 2,300,000

Convertible Notes (Details)

Convertible Notes (Details) - USD ($)	Nov. 30, 2017	Aug. 31, 2017	Nov. 30, 2016
Total short-term carrying value of convertible notes			$ 2,394,849
Total long-term carrying value of convertible notes			231,517
Series E [Member]
Principal		$ 30,000	180,000
Fair value embedded conversion
Debt discount		(5,477)	(124,164)
Carrying value of Series A Notes		$ 24,523	55,836
Series A [Member]
Principal			12,500
Fair value embedded conversion			12,000
Debt discount			(2,194)
Carrying value of Series A Notes			22,306
Series B [Member]
Principal			55,000
Fair value embedded conversion			55,000
Debt discount			(19,229)
Carrying value of Series A Notes			90,771
Series C [Member]
Principal			576,383
Fair value embedded conversion			838,000
Debt discount			(250,969)
Carrying value of Series A Notes			1,163,414
Series D [Member]
Principal			160,000
Fair value embedded conversion
Debt discount			(140,961)
Carrying value of Series A Notes			19,039
Secured Convertible Debenture [Member]
Principal			1,500,000
Fair value embedded conversion			72,000
Debt discount			(297,000)
Carrying value of Series A Notes			$ 1,275,000

Convertible Notes (Details 1)

Convertible Notes (Details 1) - $ / shares	9 Months Ended	12 Months Ended
	Aug. 31, 2016	Nov. 30, 2017	Nov. 30, 2016
Stock price		$ 3.43
Terms (years)		1 year 6 months
Volatility		116.77%
Dividend yield		0.00%
Minimum [Member]
Stock price	$ 2.60	$ 4.93	$ 2.60
Volatility	11677.00%	14426.00%	11677.00%
Risk-free rate	0.51%	53.00%	48.00%
Dividend yield	0.00%	0.00%	0.00%
Maximum [Member]
Stock price	$ 3.26	$ 7.05	$ 3.26
Volatility		15735.00%	16349.00%
Risk-free rate	76.00%	76.00%	80.00%

Convertible Notes (Details 2)

Convertible Notes (Details 2) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Notes to Financial Statements
Balance, Beginning of year	$ 977,000	$ 229,000
Issuance	86,000	1,303,000
Net unrealized gain/(loss)	812,017	(121,000)
Conversion	(1,873,017)	(434,000)
Balance at May 31, 2017		$ 977,000

Convertible Notes (Details 4)

Convertible Notes (Details 4) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Principal of conversion of debts	$ 4,983,883	$ 196,117
Shares of conversion of debts	1,650,379	118,128
Series A [Member]
Principal of conversion of debts	$ 12,500	$ 37,500
Shares of conversion of debts	5,936	22,148
Series B [Member]
Principal of conversion of debts	$ 55,000	$ 100,000
Shares of conversion of debts	27,995	51,111
Series C [Member]
Principal of conversion of debts	$ 576,383	$ 58,617
Shares of conversion of debts	407,484	44,869
Series D [Member]
Principal of conversion of debts	$ 160,000
Shares of conversion of debts	91,782
Series E [Member]
Principal of conversion of debts	$ 180,000
Shares of conversion of debts	76,455
Secured Convertible Debenture [Member]
Principal of conversion of debts	$ 4,000,000
Shares of conversion of debts	1,040,727

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Nov. 30, 2017	Nov. 30, 2016	Nov. 29, 2016
Conversion price			1.25
Aggregate principal balance	$ 2,000			$ 150,000
Debt discount		$ 750,000
Interest expense	97,000	171,000	$ 526,000	262,000
Embedded conversion option has a fair value			(810,017)	121,000
Conversion of note			89,000
Loss on extinguishment of debt			$ 481,000
Series A [Member]
Conversion price			1.25
Interest expense			$ 10
Series C [Member]
Conversion price			1.25
Aggregate principal balance	550,000			550,000
Interest expense			$ 10
Series D [Member]
Conversion price			1.85
Aggregate principal balance		$ 160,000		$ 134,000
Interest expense			$ 10
Conversion of note			$ 160,000
Series E [Member]
Conversion price				2.50
Aggregate principal balance				$ 180,000
Debt discount				750,000
Interest expense				10
Conversion of note				141,000
Series B [Member]
Aggregate principal balance	$ 105,000
Secured Convertible Debenture [Member]
Aggregate principal balance				$ 1,500,000	$ 4,000,000
Debt discount					$ 731,000

Note Payable (Details Narrative

Note Payable (Details Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2017	Aug. 31, 2017	Nov. 30, 2016
Debt Disclosure [Abstract]
Aggregate principal balance		$ 2,000	$ 150,000
Restricted shares issued	15,000
Common stock for cash proceeds	$ 150,000
Common stock issued fair value			$ 15,000
Additional paid in capital	$ 52,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Aug. 31, 2017	May 31, 2015	Aug. 31, 2017	Nov. 30, 2017	Nov. 30, 2016
Research and development expenses	$ 7,500			$ 18,000
Warrant Purchased				100,000
Exercise price				$ 3
Common stock to a related party for advisory services				6,399,585	3,301,114
General and administrative expenses		$ 20,000		$ 1,260,000
License Agreement Mannin [Member]
Research and development expenses	525,000		$ 1,400,000
License Agreement Bio Nucleonics [Member]
Research and development expenses	$ 144,000		$ 352,500

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Nov. 30, 2017	Nov. 30, 2016
Related Party Transactions [Abstract]
Related party transaction	$ 117,500	$ 112,132	$ 360,000	$ 215,375

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Details Narrative) - $ / shares	Nov. 30, 2017	Aug. 31, 2017	Nov. 30, 2016
Disclosure Text Block [Abstract]
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000	250,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000	100,000,000

Warrants (Details 2)

Warrants (Details 2)	12 Months Ended
	Nov. 30, 2017USD ($)
Notes to Financial Statements
Fair value of warrant liability at November 30, 2016	$ 168,070
Issuance of new warrant liability
Change in fair value of warrant liability	59,870
Reclassification of warrant liability to equity	(227,940)
Fair value of warrant liability at May 31, 2017

Warrants (Details)

Warrants (Details)	12 Months Ended
	Nov. 30, 2017USD ($)$ / sharesshares
Warrants
Outstanding at November 30, 2016 | shares	1,047,500
Issued | shares	2,056,495
Exercised | shares	(20,000)
Outstanding at November 30, 2017 | shares	3,083,995
Exercisable at November 30, 2017 | shares	2,323,245
Weighted Average Exercise Price
Outstanding at November 30, 2016	$ 2.54
Issued	4.25
Exercised	3.50
Outstanding at May 31, 2017	3.67
Exercisable at May 31, 2017	3.56
Intrinsic Value
Outstanding at November 30, 2016	1,158,000
Issued	$ 512,960
Exercised | $	$ 19,800
Outstanding at May 31, 2017	$ 2,539,185
Exercisable at May 31, 2017	$ 2,170,618
Weighted Average Remaning Contractual Life (years)
Outstanding at November 30, 2016	4 years 1 month 6 days
Issued	4 years 5 months 6 days
Outstanding at May 31, 2017	4 years 7 days
Exercisable at May 31, 2017	3 years 10 months 8 days

Warrants (Details 1)

Warrants (Details 1) - $ / shares	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Dividend yield	0.00%	0.00%
Minimum [Member]
Stock price	$ 3.40	$ 1.60
Terms (years)	1 year 9 months	2 years
Volatility	129.64%	101.13%
Risk-free rate	1.42%	0.76%
Maximum [Member]
Stock price	$ 5.60	$ 4.15
Terms (years)	5 years	5 years
Volatility	143.47%	138.69%
Risk-free rate	2.14%	1.83%

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Notes to Financial Statements
General and administrative expenses	$ 6,122,565	$ 3,637,868

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Nov. 30, 2017	Nov. 30, 2016
Deferred tax assets:
Net-operating loss carryforward	$ 885,120	$ 3,810,498
Stock-based compensation	1,685,262	4,466,254
License agreement	293,433	595,780
Tax amortization for license agreement		(102,747)
Charitable contributions		387
Total Deferred Tax Assets	2,863,815	8,770,172
Valuation allowance	(2,863,815)	(8,770,172)
Deferred Tax Asset, Net of Allowance

Income Taxes Details 1)

Income Taxes Details 1)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Income Tax Disclosure [Abstract]
Statutory Federal Income Tax Rate	(3400.00%)	(3400.00%)
State and Local Taxes, Net of Federal Tax Benefit	(1030.00%)	(470.00%)
Loss on conversion of debt	1.4	0.5
Gain/ loss on extinguishment of convertible note	20.00%	(70.00%)
Change in value of embedded conversion option and related accetion of interest expense	440.00%	160.00%
Change in fair value of warrant liability	20.00%	0.00%
Loss on modification of Private Placement Units	0.00%	20.00%
Loss on issuance of convertible debt	0.00%	260.00%
Non-U.S. operations	30.00%	0.00%
Change in Valuation Allowance	3780.00%	3450.00%
Income Taxes Provision (Benefit)	0.00%	0.00%

Subsequent Events (Detail Narra

Subsequent Events (Detail Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2017	Feb. 01, 2018	Oct. 16, 2017	Sep. 01, 2017	Nov. 30, 2016
Subsequent Events [Abstract]
Convertible note to a third party				$ 100,000
Aggregate shares		1,711,875	500,000		31,000
Technology License and Purchase Option Agreement	$ 50,000
Principal of Series E notes issued	150,000
Private Placement gross proceeds	142,662
Total cash payment	$ 100,000